Cannabis and Burn Pain
An honest look at what cannabinoids can and can't do for thermal burn pain, itch, and wound healing.
Burn pain is one of the worst pains in medicine, and patients understandably want every option. The honest answer: there is biological plausibility and a handful of small studies suggesting cannabinoids might help with neuropathic burn pain, itch, and opioid sparing — but the high-quality clinical evidence is thin. Most burn-specific claims you'll see online are extrapolated from other pain conditions or from animal work. Cannabis is not a substitute for proper burn care, and topical 'CBD burn creams' marketed for acute burns are not supported by good evidence.
Not medical advice
This article is not medical advice. Burn injuries — especially second-degree and deeper, or burns covering more than a small area — are medical emergencies. If you or someone else has a serious burn, contact emergency services or a burn center. Do not apply cannabis products, oils, or 'CBD salves' to fresh open burns in place of standard wound care. Talk to a qualified clinician (ideally one familiar with burn medicine) before adding any cannabinoid to a treatment plan, especially alongside opioids, benzodiazepines, or ketamine.
Plain-language summary
Burn pain has three overlapping components: acute nociceptive pain (the tissue damage itself), procedural pain (dressing changes, debridement, physiotherapy), and chronic post-burn pain that is often neuropathic and accompanied by intense itch. Standard care leans on opioids, ketamine, gabapentinoids, regional anesthesia, and antihistamines, with significant side effects and an incomplete response in many patients [1][2].
Cannabinoids — primarily THC and CBD — act on the endocannabinoid system, which is present in skin, peripheral nerves, and central pain pathways [3]. That biological story is real. The clinical story is much smaller: a few case reports, small observational studies, and trials borrowed from other pain conditions. There is no large randomized controlled trial of cannabis specifically for burn pain as of 2024 No data.
What probably works
Honestly, nothing in the cannabis category has crossed the bar of 'probably works' for burn pain specifically. We will not pretend otherwise.
What does probably work for burn pain in general — and is the comparator any cannabinoid would need to beat or complement — includes opioids, ketamine, regional anesthesia, gabapentin/pregabalin for neuropathic components, and structured non-pharmacological interventions like virtual reality during dressing changes [1][2][4] Strong evidence.
What might work (weak evidence)
Chronic neuropathic post-burn pain. Cannabinoids have modest evidence in chronic neuropathic pain from other causes (HIV neuropathy, MS, post-traumatic). A Cochrane review found small benefits with significant side effects [5] Weak / limited. Burn-related neuropathic pain shares mechanisms, so extrapolation is reasonable but unproven.
Post-burn itch (pruritus). Pruritus affects a majority of burn survivors and is often refractory. Small studies of topical cannabinoid-containing creams (e.g., palmitoylethanolamide, an endocannabinoid-related lipid) have reported reductions in itch [6] Weak / limited. PEA is not THC or CBD, but it is part of the same signaling family. Oral cannabinoids have been tried for refractory pruritus in case series with mixed results Anecdote.
Opioid sparing. Observational data from chronic pain populations suggest some patients reduce opioid use when cannabis is added [7]. Whether this transfers to acute burn care — where opioid doses are high and rapidly titrated — is not established Weak / limited.
Anxiety and sleep during recovery. Burn recovery involves prolonged hospitalization, PTSD risk, and disturbed sleep. Cannabinoids have modest, inconsistent evidence for sleep and anxiety [8] Weak / limited.
What doesn't work or has weak/no evidence
Topical CBD oil on fresh open burns. Marketed widely. Not supported by clinical evidence. Carrier oils can trap heat, introduce contaminants into open wounds, and interfere with assessment of burn depth. Don't No data.
Cannabis 'accelerates wound healing.' There is preclinical (cell and rodent) work suggesting cannabinoid receptors are involved in skin repair [9]. There is no robust human trial showing that applying or ingesting cannabinoids speeds burn wound healing [evidence:weak to none].
Smoked cannabis for acute burn pain. No controlled evidence. Smoke inhalation is contraindicated in patients with any inhalation injury, which is common in burn patients. Avoid.
'Indica strains are better for pain.' Marketing folklore. The indica/sativa label does not reliably predict chemistry or effect [10] Disputed.
Specific THC:CBD ratios for burns. No burn-specific ratio has been validated. Claims otherwise are extrapolation at best.
What we don't know
- Whether adjunctive cannabinoids reduce opioid requirements during acute burn hospitalization.
- Whether topical cannabinoid formulations help re-epithelialized (closed) burn scars with pruritus or hypertrophic scarring.
- Optimal dose, route, and timing — every published case is essentially a different protocol.
- Interactions with the heavy polypharmacy of burn ICU (opioids, ketamine, benzodiazepines, propofol, anticoagulants metabolized via CYP enzymes that CBD inhibits [11]).
- Effects on infection risk in immunocompromised burn patients.
These are not rhetorical gaps. They are the actual reason burn societies have not endorsed cannabis as standard care.
Comparison with standard treatments
| Treatment | Evidence for burn pain | Typical role | |---|---|---| | Opioids (morphine, fentanyl) | Strong | First-line acute and procedural | | Ketamine | Strong | Procedural, opioid-sparing | | Regional anesthesia | Strong | Large burns, grafting | | Gabapentinoids | Moderate | Neuropathic and itch components | | Antihistamines, gabapentin, doxepin | Moderate | Pruritus | | Virtual reality, hypnosis | Moderate | Non-drug adjunct, especially dressing changes [4] | | Cannabinoids (oral THC/CBD) | Weak | Possible adjunct in chronic phase; not standard | | Topical cannabinoids on open wounds | None | Not recommended |
The honest framing: cannabis is, at best, an adjunct to consider in the chronic phase for patients with neuropathic pain or itch that has failed first-line therapy. It is not a replacement for any pillar of standard burn analgesia.
Risks
- Drug interactions. CBD inhibits CYP3A4 and CYP2C19, affecting levels of many drugs used in burn care, including some anticoagulants and antiepileptics [11].
- Sedation stacking. Adding cannabinoids to opioids, benzodiazepines, and ketamine increases sedation and respiratory risk.
- Inhalation. Smoking or vaping is contraindicated in anyone with airway injury, which is common after fire/smoke exposure.
- Wound contamination. Non-sterile topical products on open burns risk infection. Burn wounds are a known portal for serious infection.
- Tachycardia and hypotension. THC can cause both, complicating fluid resuscitation in large burns.
- Psychiatric effects. Burn patients are at high risk for PTSD, anxiety, and delirium. THC can worsen anxiety and precipitate psychosis in vulnerable patients [12].
- Cannabinoid hyperemesis syndrome. In heavy chronic users, paradoxical vomiting complicates recovery.
These risks are manageable in a clinical setting with disclosure and monitoring. They are not manageable when patients self-treat without telling their burn team.
Bottom line
Cannabis is biologically plausible for several aspects of burn pain and itch, particularly in the chronic phase. The clinical evidence is weak and almost entirely extrapolated. It should not replace standard burn analgesia, should not be applied to open burns as a topical, and should be disclosed to your burn team if used. If you want to read more on the underlying pharmacology and pain mechanisms, see Cannabis and Chronic Pain, Cannabis and Neuropathic Pain, and The Endocannabinoid System.
Sources
- Peer-reviewed Griggs C, Goverman J, Bittner EA, Levi B. Sedation and pain management in burn patients. Clinics in Plastic Surgery. 2017;44(3):535-540.
- Peer-reviewed James DL, Jowza M. Principles of burn pain management. Clinics in Plastic Surgery. 2017;44(4):737-747.
- Peer-reviewed Bíró T, Tóth BI, Haskó G, Paus R, Pacher P. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends in Pharmacological Sciences. 2009;30(8):411-420.
- Peer-reviewed Scapin SQ, Echevarría-Guanilo ME, Boeira Fuculo Junior PR, et al. Virtual reality in the treatment of burn patients: A systematic review. Burns. 2018;44(6):1403-1416.
- Peer-reviewed Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews. 2018;3(3):CD012182.
- Peer-reviewed Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). Journal of the European Academy of Dermatology and Venereology. 2008;22(1):73-82.
- Peer-reviewed Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. Journal of Pain. 2016;17(6):739-744.
- Peer-reviewed National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017.
- Peer-reviewed Wang LL, Zhao R, Li JY, et al. Pharmacological activation of cannabinoid 2 receptor attenuates inflammation, fibrogenesis, and promotes re-epithelialization during skin wound healing. European Journal of Pharmacology. 2016;786:128-136.
- Peer-reviewed Watts SE, Vidaurre J, Goldberg E, et al. The cannabis conundrum: thinking outside the THC box. Journal of Clinical Pharmacology. 2021;61(3):282-289.
- Peer-reviewed Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine. 2019;8(7):989.
- Peer-reviewed Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427-436.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Chronic Pain — What the evidence actually says about cannabis for long-term pain, separated from the mark...
- Cannabis and Neuropathic Pain — What the evidence actually says about using cannabis to treat nerve pain, by condition and...